Table 1.
Patient Characteristics
| SARS-Cov-2 S antibody Response |
P Value | ||||
|---|---|---|---|---|---|
| Overall | High | Low | Negative | ||
| N | 145 | 99 | 25 | 21 | |
| Age at vaccination, median (range) | 61 (24, 80) | 59 (24, 79) | 61 (24, 75) | 66 (24, 80) | .039 |
| Gender | .29 | ||||
| Female | 69 (48%) | 51 (52%) | 11 (44%) | 7 (33%) | |
| Male | 76 (52%) | 48 (48%) | 14 (56%) | 14 (67%) | |
| Race | .052 | ||||
| Caucasian, Non-Hispanic | 100 (69%) | 62 (63%) | 21 (84%) | 17 (81%) | |
| Hispanic or non-Caucasian | 45 (31%) | 37 (37%) | 4 (16%) | 4 (19%) | |
| Underlying disease | >.99 | ||||
| ALL | 14 (9.7%) | 9 (9.1%) | 3 (12%) | 2 (9.5%) | |
| AML | 69 (48%) | 49 (49%) | 11 (44%) | 9 (43%) | |
| Lymphoma | 17 (12%) | 11 (11%) | 3 (12%) | 3 (14%) | |
| MDS and MPD | 41 (28%) | 26 (26%) | 8 (32%) | 7 (33%) | |
| Severe aplastic anemia | 3 (2.1%) | 3 (3.0%) | 0 (0%) | 0 (0%) | |
| Sickle cell disease | 1 (0.7%) | 1 (1.0%) | 0 (0%) | 0 (0%) | |
| Type of Transplant | .13 | ||||
| MRD | 47 (32%) | 35 (35%) | 8 (32%) | 4 (19%) | |
| MUD | 53 (37%) | 30 (30%) | 13 (52%) | 10 (48%) | |
| Haplo/Cord | 45 (31%) | 34 (34%) | 4 (16%) | 7 (33%) | |
| Median Days from First Vaccine Dose to initial SARS-CoV-2 S antibody, median (range) | 123 (20, 400) | 129 (20, 400) | 114 (61, 283) | 128 (65, 254) | .75 |
| Conditioning regimen | .06 | ||||
| Myeloablative | 13 (9.0%) | 9 (9.1%) | 2 (8.0%) | 2 (9.5%) | |
| FluMel | 42 (29%) | 36 (36%) | 2 (8.0%) | 4 (19%) | |
| FluMelTBI | 86 (59%) | 51 (52%) | 20 (80%) | 15 (71%) | |
| Non-myeloablative | 4 (2.8%) | 3 (3.0%) | 1 (4.0%) | 0 (0%) | |
| SARS-CoV-2 N antibody | .38 | ||||
| Negative | 84 (82%) | 53 (80%) | 16 (76%) | 15 (94%) | |
| Positive | 19 (18%) | 13 (20%) | 5 (24%) | 1 (6.2%) | |
| Missing | 42 | 33 | 4 | 5 | |
| Lymphocytes, median (range) | 1.40 (0.04, 4.96) | 1.73 (0.10, 4.96) | 0.70 (0.04, 2.13) | 0.70 (0.10, 3.20) | <.001 |
| Lymphocytes | <.001 | ||||
| < 1 × 106/mL | 47 (32%) | 17 (17%) | 16 (64%) | 14 (67%) | |
| ≥ 1 × 106/mL | 98 (68%) | 82 (83%) | 9 (36%) | 7 (33%) | |
| Months from transplant to first vaccine, median (range) | 31 (3, 111) | 38 (3, 110) | 13 (4, 71) | 11 (3, 111) | <.001 |
| Type of vaccine | .61 | ||||
| JNJ-78436735 | 8 (5.5%) | 6 (6.1%) | 1 (4.0%) | 1 (4.8%) | |
| MRNA-1273 | 48 (33%) | 36 (36%) | 8 (32%) | 4 (19%) | |
| BNT162b2 | 89 (61%) | 57 (58%) | 16 (64%) | 16 (76%) | |
| Chemotherapy | .11 | ||||
| No | 130 (90%) | 91 (92%) | 23 (92%) | 16 (76%) | |
| Yes | 15 (10%) | 8 (8.1%) | 2 (8.0%) | 5 (24%) | |
| Maintenance treatment | .066 | ||||
| No | 129 (90%) | 92 (94%) | 21 (84%) | 16 (80%) | |
| Yes | 14 (9.8%) | 6 (6.1%) | 4 (16%) | 4 (20%) | |
| Acute GVHD | .54 | ||||
| No | 143 (99%) | 98 (99%) | 24 (96%) | 21 (100%) | |
| Yes | 2 (1.4%) | 1 (1.0%) | 1 (4.0%) | 0 (0%) | |
| Chronic GVHD | <.001 | ||||
| No | 123 (85%) | 94 (95%) | 18 (72%) | 11 (52%) | |
| Yes | 22 (15%) | 5 (5.1%) | 7 (28%) | 10 (48%) | |
| GVHD Treatment | <.001 | ||||
| No | 126 (87%) | 93 (94%) | 20 (80%) | 13 (62%) | |
| Yes | 17 (12%) | 5 (5.1%) | 5 (20%) | 7 (33%) | |
| Covid after vaccination | .055 | ||||
| No | 135 (93%) | 95 (96%) | 21 (84%) | 19 (90%) | |
| Yes | 10 (6.9%) | 4 (4.0%) | 4 (16%) | 2 (9.5%) | |
| Remission | .048 | ||||
| No | 17 (12%) | 9 (9.1%) | 2 (8.3%) | 6 (29%) | |
| Yes | 127 (88%) | 90 (91%) | 22 (92%) | 15 (71%) | |
| Pretransplantation rituximab | .002 | ||||
| No | 87 (60%) | 69 (70%) | 9 (36%) | 9 (43%) | |
| Yes | 58 (40%) | 30 (30%) | 16 (64%) | 12 (57%) | |
| Time from transplantation to first vaccine | <.001 | ||||
| >12 months | 117 (81%) | 94 (95%) | 13 (52%) | 10 (48%) | |
| 6-12 months | 14 (9%) | 3 (20%) | 6 (43%) | 5 (37%) | |
| 3-6 months | 14 (9%) | 2 (14%) | 6 (43%) | 6 (43%) | |
TBI indicates total body irradiation; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome.